Texas ranked last for telemedicine

Texas has the dubious distinction of being ranked last among states when it comes to telemedicine implementation. 

Texas, Alabama and Arkansas all received grades of "F" from the American Telemedicine Association, as noted in a report from the National Center for Policy Analysis (NCPA). All other states but Georgia which earned a “C,” earned “As” and “Bs.”

But, Texas has "strongly resisted efforts to expand telemedicine in the state’s private health sector,” according to the report.

Texas, Alabama and Georgia are the only states that require an in-office follow-up visit after a telemedicine encounter. "This is striking considering Texas ranks 51 out of 51 (including Washington, D.C.) for access to medical care in the United States," the report says.

In January 2015, the Texas Medical Board prohibited doctors from writing prescriptions for telemedicine patients who did not have a previous relationship, including an in-person visit. Regulations also require in-office follow-up visits.

The restrictions came as nearly 13 percent of the state's population has been designated as medically underserved, meaning that an individual's circumstances make it difficult to either access or afford health care services, the report said.

The report says the holdup of telemedicine implementation is undermining healthcare accessibility goals of Texas.

"The protectionist policies of the Texas Medical Board (TMB) threaten to undermine the effort Texas has made to increase access to medical care through telemedicine," wrote Jennifer Vermeulen, an NCPS research associate. "With the population of Texas projected to double by 2050, attempting to limit telemedicine patients and providers is a dangerous bet against the future of healthcare in Texas."

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.